This project investigates immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs) for skin cancer. These side effects can affect nearly all organs and may lead to the discontinuation of therapy. Although corticosteroids (glucocorticoids) are commonly used, they weaken the immune system and can impair the efficacy of ICI treatment. The goal of the project is to identify new molecular targets in tissue samples and blood to develop personalized treatment approaches. Using advanced methods, we analyze the immune cells involved in skin-related irAEs, as well as in other organs (e.g. intestine). This aims to identify new therapeutic targets, such as specific signaling molecules or cell receptors, to enable improved treatments for irAEs across different cancers.

Here you can find further information.